Ringpu Bio-technology Changed Business Focus and Marketized Animal Vaccine Revenue Held 77.7% - ResearchInChina

Search by Type

Report Charts News

*

Search by Company

Code Company name

Category

Home>>News>>Life Sciences>>Biotechnology>>Vaccine

Remember Me Next Time

Ringpu Bio-technology Changed Business Focus and Marketized Animal Vaccine Revenue Held 77.7%

Date:2012-04-09 Source:

Related Company

Tianjin Ringpu Bio-technology Co.,Ltd.(300119.SZ)

At present, state bidding vaccine takes up about 70% of animal vaccine market. Under the fierce m...

Welcome to our website. This service is open to member only.

Registration

Contact our customer service team
Tel: 86-10-82600828, 82600893
Fax: 86-10-82601570
Email: report@researchinchina.com

Related Reports

China Heparin Industry Report, 2010-20112011-09-28
China Blood Products Industry Report, 2010-20112011-09-05
China Monoclonal Antibody Industry Report, 2010-20112011-07-05
China Insulin Industry Report, 20102011-01-25
China Heparin Industry Report, 20102010-12-18
China Blood Products Industry Report, 20102010-11-10
Global and China Biopharmaceutical Industry Report, 20102010-09-16
China Blood Products Industry Report, 20092009-10-13

Related News

Ringpu Bio-technology Changed Business Focus and Marketized Animal Vaccine Revenue Held 77.7%2012-04-09
Muscovy Duck Parvovirus Vaccine to Launch into Market2012-03-31
BioDiem licenses LAIV technology to Changchun BCHT2012-02-10
Bexsero to protect against meningococcal serogroup B disease2012-02-08
Clinical trial to begin for Sumagen's HIV vaccine2012-01-11
JE vaccine: Hope on the anvil2011-12-05
Australian scientists discover disease-fighting helper cell2011-11-28
Pfizer, China's Guoyuan to create animal vaccine joint venture2011-09-14

Contact us | Copyright | Privacy policy | Buy Reports | Member Service | Mailing List

2005-2011 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1